首页 / 专利分类库 / 有机化学 / 无环或碳环化合物 / 含有至少具有1个氮-氮重键的至少两个氮原子的链的化合物
序号 专利名 申请号 申请日 公开(公告)号 公开(公告)日 发明人
181 Liquid crystal compounds having ether tail moiety EP87110034.3 1987-07-11 EP0258578A3 1989-05-10 Cumming, William J.; Gaudiana, R. A.; McGowan, Cynthia; Minns, Richard A.; Naiman, Alaric

Disclosed are smectic liquid crystal compounds exhibiting ferroelectric behaviour and having the formula wherein R1 is alkyl or alkoxyalkyl, R2 and R3 are each alkylene, a is an integer of at least one, b is zero or one, R' is an optically active group containing an asymmetric center and-Z- is an organic divalent core radical having parallel or coaxially extending bonds at the terminal ends thereof, the core radical having an axial ratio of at least two and being characterized by an essentially rigid and flat molecular structure. Presence of the ether-interrupted hydrocarbon tail moiety at the terminal end of the compounds provides a lowering in observed temperatures of phase transition.

182 OPTICALLY ACTIVE, ANTI HEAD-TO-HEAD COUMARIN DIMER-POLYAMIDES EP85900728.8 1985-01-07 EP0207993A1 1987-01-14 SAIGOU, Kazuhiko; YONEZAWA, Noriyuki; KANOE, Toshio; SEKIMOTO, Kazuhiro

Optically active, anti head-to-head coumarin dimers represented by general formula (I) or (II): a process for their preparation, optically active polyamides represented by general formula (III) or (IV), (wherein A represents a primary or secondary amine residue, and n represents an integer of 2 or more) and a process for their preparation from (I) or (II).

183 Reagents, test kits and methods for the detection of cannabinoids EP84304306.8 1984-06-26 EP0132313A2 1985-01-30 Spiro, Baruch

The invention provides a stable solid reagent for use in a prepackaged test kit for the detection of cannabinoids comprising a diazonium salt which undergoes characteristic color change when combined with a cannabinoid under basic conditions, the salt comprising an anion capable of causing the entire salt including the diazonium cation thereof to dissolve in an organic solvent when combined therewith to form a stable liquid reagent for the detection of cannabinoids. The invention also provides a stable liquid reagent comprising the aforementioned diazonium salt and an organic solvent as well as providing prepackaged reagent test kits containing the aforementioned reagents and methods for detecting cannabinoids using the reagents of the invention.

184 Azophenols as ERG oncogene inhibitors AU2016319111 2016-09-09 AU2016319111B2 2021-05-06 DOBI ALBERT L; DALGARD CLIFTON; SRIVASTAVA SHIV
Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II), wherein X, X1, X2, X3, X4, X5, R1 through R4 and R9 are as described. An aspect of the present invention relates to a method for treating a disease associated with overexpression of wild type ERG protein, an altered ERG protein, ERG gene transcription or ERG mRNA translation in a subject suffering therefrom, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or Formula (II)
185 ACYLHYDRAZONES FOR THE TREATMENT OF NEUROLOGICAL DISEASES CA3114555 2019-09-27 CA3114555A1 2020-04-02 PEREZ FERNANDEZ RUTH; CANAL MARTIN ANDREA; SANCHEZ BARRENA MARIA JOSE; MANSILLA APARICIO ALICIA
The invention relates to a group of compounds with a structural nucleus of acylhydrazone, which are capable of modulating the interaction between the proteins NCS-1 and Ric8a involved in the process of regulating the number of synapses and the probability of release of neurotransmitters. These compounds can therefore be used for the treatment of neurological diseases in which the number of synapses is affected, such as Alzheimer's disease, Huntington's disease or Parkinson's disease.
186 AZOPHENOLS AS ERG ONCOGENE INHIBITORS CA2981188 2016-09-09 CA2981188A1 2017-03-16 DOBI ALBERT L; DALGARD CLIFTON; SRIVASTAVA SHIV
Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II), wherein X, X1, X2, X3, X4, X5, R1 through R4 and R9 are as described. An aspect of the present invention relates to a method for treating a disease associated with overexpression of wild type ERG protein, an altered ERG protein, ERG gene transcription or ERG mRNA translation in a subject suffering therefrom, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or Formula (II)
187 АЗО-БІС-[ІЗОБУТИРООКСАДІАЗОЛІНІЛЦИКЛОГЕКСИЛКАРБАМАТ-(1-ГЕКСАМЕТИЛЕН-3,5-ДИГЕКСАМЕТИЛЕНІЗОЦІАНАТ)ЦІАНУРАТ] ЯК ІНІЦІАТОР РАДИКАЛЬНОЇ ПОЛІМЕРИЗАЦІЇ ВІНІЛОВИХ МОНОМЕРІВ UAU201403468 2014-04-04 UA92918U 2014-09-10 HRYSCHENKO VOLODYMYR KOSTIANTYNOVYCH; BUSKO NATALIA ANATOLIIVNA; SILCHENKO YURII OLEKSIIOVYCH; HUDZENKO NATALIA VASYLIVNA; KOCHETOVA YAROSLAVA VASYLIVNA; BARANTSOVA ANTONINA VIKTORIVNA
Азо-біс-[ізобутирооксадіазолінілциклогексилкарбамат-(1-гексаметилен-3,5-дигексаметиленізоціанат)ціанурат] якініціаторрадикальноїполімеризаціївініловихмономерів.
188 INFLAMMATORY CYTOKINE RELEASE INHIBITOR CA2431083 2001-12-18 CA2431083C 2011-08-09 MUTO SUSUMU; NAGANO TATSUO; SOTOME TOMOMI; ITAI AKIKO
A medicament having inhibitory activity against NF- .kappa. B activation, which comprises a compound represented by the following general formula (I) or a pharmacologically acceptable salt as an active ingredient: (see formula I) wherein X represents a connecting group, A represents hydrogen atom or acetyl group, E represents an aryl group or a heteroaryl group, and ring X represents an arene or a heteroarene.
189 ПЕРФТОРАРОМАТИЧЕСКИЕ ИЗОМЕРНЫЕ АЗОБИСФЕНОЛЫ КАК МОНОМЕРЫ ДЛЯ ПОЛИУРЕТАНОВ UAU201100359 2011-01-12 UA61268U 2011-07-11 SHEVCHENKO VALERII VASYLIOVYCH; TKACHENKO IHOR MYKHAILOVYCH; SYDORENKO OLEKSANDR VASYLIOVYCH; KONONEVYCH YURII MYKOLAIOVYCH; SHEKERA OLEH VASYLOVYCH
Перфторароматическиеизомерныеазобисфенолыобщейформулы EMBED ISISServer , где 1 - n-АБФ, 2 - м-АБФи 3 - о-АБФкакмономерыдляполиуретанов.
190 ПЕРФТОРАРОМАТИЧЕСКИЕ ИЗОМЕРНЫЕ БИСФЕНОЛЫ С АЗОГРУППАМИ КАК МОНОМЕРЫ ДЛЯ ПОЛИЭТЕРУРЕТАНОВ UAU201004461 2010-04-16 UA53567U 2010-10-11 SHEVCHENKO VALERII VASYLIOVYCH; TKACHENKO IHOR MYKHAILOVYCH; KONONEVYCH YURII MYKOLAIOVYCH; SYDORENKO OLEKSANDR VASYLIOVYCH; SHEKERA OLEH VASYLOVYCH
Перфторароматическиеизомерныебисфенолыс азогруппамикакмономерыдляполиэтеруретанов.
191 АМИД 2,2'-АЗО-БИС-ИЗОМАСЛЯНОЙ КИСЛОТЫ КАК ИНИЦИАТОР РАДИКАЛЬНОЙ ПОЛИМЕРИЗАЦИИ ДИЕНОВЫХ И ВИНИЛОВЫХ МОНОМЕРОВ UAU200906369 2009-06-19 UA47180U 2010-01-25 HRYSCHENKO VOLODYMYR KOSTIANTYNOVYCH; HUDZENKO NATALIA VASYLIVNA; BARANTSOVA ANTONINA VIKTORIVNA; BUSKO NATALIA ANATOLIIVNA
Амид 2,2'-азо-бис-изомаслянойкислотыкакинициаторрадикальнойполимеризациидиеновыхи виниловыхмономеров.
192 АНТАГОНИСТЫ МУСКАРИНОВЫХ АЦЕТИЛХОЛИНОВЫХ РЕЦЕПТОРОВ RU2006129289 2005-01-13 RU2006129289A 2008-02-20
193 Nowe związki, pochodne kwasu fumarowego oraz sposób wytwarzania nowych związków, pochodnych kwasu fumarowego PL34587001 2001-02-13 PL192547B1 2006-11-30 BLUS KAZIMIERZ; WOJCIECHOWSKA ALEKSANDRA; WOJCIECHOWSKI KRZYSZTOF
194 Sposób wytwarzania nowych związków, pochodnych kwasu fumarowego PL34590901 2001-02-14 PL192540B1 2006-11-30 BLUS KAZIMIERZ; WOJCIECHOWSKA ALEKSANDRA; WOJCIECHOWSKI KRZYSZTOF
195 NOVI N-MONOSUPSTITUISANI CIJANOACETAMIDI I POSTUPAK ZA NJIHOVO DOBIJANJE YUP76803 2003-09-30 YU76803A 2006-05-25 MARINKOVIC ALEKSANDAR; MIJIN DUSAN; NEDELJKOVIC JELENA; PETROVIC SLOBODAN
Postupak za dobijanje novih supstituisanih N-supstituisanih-2-cijanoacetamida opšte formule (I) u kojoj R predstavlja s-butil, alil, cikloheksil, 4-hidroksifenil, 4-sulfonilfenil, 4-karboksifenil i 4-acetilfenil.[Method of preparation of new substituted N-substituted-2-cyanoacetamides having general formula as in (1) Wherein R represents s-butyl, allyl, cyclohexyl, 4-hydroxyphenyl, 4-sulphonylphenyl, 4-carboxyphenyl and 4-acetyphenyl.
196 Immunoregulatory Compounds and Derivatives and methods of treating diseases therewith AU2005244526 2005-12-14 AU2005244526A1 2006-01-12 RIGGS-SAUTHIER JENNIFER; ELWURIBE NNOCHIRI N
197 Peptide deformylase inhibitors AU2002335490 2002-03-01 AU2002335490B2 2005-10-20 XIANG JIA-NING; LEE JINHWA; MERCER DANIEL J; CHRISTENSEN SIEGFRIED B
198 PEPTIDE DEFORMYLASE INHIBITORS PL36456302 2002-03-01 PL364563A1 2004-12-13 XIANG JIA-NING; CHRISTENSEN SIEGFRIED B; LEE JINHWA; MERCER DANIEL J
199 PROCESS FOR CONTROLLING PARTICLE SIZE OF NAPTHOQUINONE DIAZIDE MYPI19985777 1998-12-21 MY114500A 2002-10-31 JOSEPH E OBERLANDER
A PROCESS FOR PRODUCING A NAPHTHOQUINONE DIAZIDE ESTER OF A PHENOLIC COMPOUND THAT IS USEFUL IN A PHOTORESIST COMPOSITION, WHICH PROCESS COMPRISES PROVIDING A NAPHTHOQUINONE DIAZIDE ESTER SOLUTION IN AN ORGANIC POLAR SOLVENT; ADDING THE RESULTING NAPHTHOQUINONE DIAZIDE ESTER SOLUTION TO A PRECIPITATION BATH THAT IS MAINTAINED AT A TEMPERATURE OF FROM ABOUT 0OC TO ABOUT -30OC; AND FILTERING THE RESULTING NAPHTHOQUINONE DIAZIDE ESTER.
200 Chemical compounds and pharmaceutical compositions for release of drugs DE68929117 1989-03-31 DE68929117T2 2000-08-24 MILLS RANDELL L
QQ群二维码
意见反馈